Programs Diabetes – SGLT2 Inhibitor


Diabetes is a leading international health concern with an estimated 422 million adults or 8.5% of the population afflicted with this disease. According to the International Diabetes Federation, an estimated 4.9 million people died as a result of diabetes in 2014.  Moreover, the cost of diabetes has risen to 825 billion dollars a year in 2016. 

Most diabetics treat their disease by controlling insulin production or regulating blood sugar through the use of medication. A diabetic patient can require up to 10 different medications at a time. Despite this large number of therapeutic options many diabetics are unable to control their disease and face significant health risks.

Sirona Biochem’s SGLT2 Inhibitor 

SGLT2 Inhibitors work differently from other, non-insulin, diabetes therapeutics which increase insulin production in the pancreas and/or affect metabolism.  SGLT2 Inhibitors act in the kidneys to reduce the re-absorption of glucose into the bloodstream. SGLT2 Inhibitors also have the potential to be strong add-on therapies to current diabetes treatments.

Using our proprietary chemistry technology, we have developed an SGLT2 Inhibitor compound: SBM-TFC-039.  Our goal is to develop a best-in-class SGLT2 Inhibitor with optimal pharmaceutical characteristics including, but not limited to, enhanced stability, bioavailability, selectivity and/or efficacy.

The first SGLT2 inhibitor to receive market approval in the U.S. was Johnson and Johnson’s SGLT inhibitor, Invokana™ (canagliflozin).  Forxiga™ (dapagliflozin), an SGLT2 inhibitor developed by AstraZeneca and Bristol-Myers Squibb received European market approval in November 2012 and was approved by the Food and Drug Administration (FDA) for the US market in January 2014. However, in June 2016, the FDA emphasized their warning on the acute kidney injury risk associated with these two medications.

SGLT2 Inhibitor Program Studies Completed

SGLT2 Milestones 15Aug2016

SGLT2 Inhibitor Results

Several studies have been conducted to demonstrate the effectiveness and stability of Sirona Biochem’s SGLT2 Inhibitor SBM-TFC-039.

In head-to-head preclinical studies, Sirona Biochem’s SBM-TFC-039 outperformed Johnson and Johnson’s canagliflozin

SGLT2 Inhibitor Licensing Deals By Third Parties

In March 2013, Johnson and Johnson’s canagliflozin (Invokana™) became the first SGLT Inhibitor to be approved by the U.S. Food and Drug Administration.  SGLT Inhibitors are a new class of drugs bringing hope to Type 2 diabetes patients who may not be getting adequate relief from currently marketed drugs.  This new SGLT Inhibitor treatment approach has resulted in significant licensing deals.  Two published SGLT Inhibitor licensing deals include:

  • Empagliflozin, one of a two-compound licensing deal between Boehringer Ingelheim and Eli Lilly for at one time payment of  €300 million and milestone payments of €625 million.
  • Dapagliflozin (Forxiga®), one of a two-compound licensing deal between Bristol Myers Squibb and AstraZeneca for upfront payment of US$100 million and milestone payments of up to US$1.25 billion
  • Bristol Myers Squibb and AstraZeneca expand licensing deal of dapagliflozin to include Japan; deal estimated to bring more than US$1 billion

Sirona’s SGLT2 Inhibitor Commercialization

In January, 2014, Sirona announced the licensing of its SGLT2 Inhibitor to Wanbang Biopharmaceuticals in China. Wanbang will develop and commercialize Sirona’s anti-diabetic SGLT2 inhibitor exclusively in the People’s Republic of China (PRC). In exchange for this license, Wanbang Biopharma has provided an upfront and will recieve milestone payments of up to US$9.5M in addition to royalty payments for product sales in the PRC. Wanbang expects to file the IND to the CFDA by the end of this year, triggering another milestone payment of $500,000 USD to Sirona.  

Sirona Biochem’s SGLT2 Inhibitor remains available for ROW agreements such as:

  • Licensing Agreements
  • Royalty Agreements
  • Acquisition of our technology
  • Joint ventures

For any additional information please contact Michelle Seltenrich at